

NEUTRA CORP.  
Form 10-Q  
December 17, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

(MARK ONE)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended October 31, 2018**

or

**TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

Commission File Number: **0-55077**

**NEUTRA CORP.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of Incorporation or organization)

**27-4505461**

(I.R.S. Employer Identification Number)

**400 South 4th Street, Suite 500**

**Las Vegas, Nevada**

(Address of principal executive offices)

**89101**

(Zip code)

Registrant's telephone number, including area code: **702-793-4121**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" or "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

(Do not check is smaller reporting company)

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Edgar Filing: NEUTRA CORP. - Form 10-Q

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of December 14, 2018, 32,181,584 shares of common stock are issued and outstanding.

---

**TABLE OF CONTENTS**

<b>PART I — FINANCIAL INFORMATION</b>	4
Item 1. Financial Statements	4
<i>Consolidated Balance Sheets</i>	4
<i>Consolidated Statements of Operations</i>	5
<i>Consolidated Statement of Stockholders' Deficit</i>	6
<i>Consolidated Statements of Cash Flows</i>	7
<i>Notes to the Unaudited Consolidated Financial Statements</i>	8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3. Quantitative and Qualitative Disclosures about Market Risk	14
Item 4. Controls and Procedures	14
<b>PART II — OTHER INFORMATION</b>	15
Item 1. Legal Proceedings	15
Item 1A. Risk Factors	15
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3. Defaults upon Senior Securities	15
Item 4. Mine Safety Disclosures	15
Item 5. Other Information	16
Item 6. Exhibits	16

## **CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION**

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2018. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

## **OTHER PERTINENT INFORMATION**

When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to Neutra Corp., a Nevada corporation.

**PART I — FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****NEUTRA CORP.****CONSOLIDATED BALANCE SHEETS****(UNAUDITED)**

	<b>October 31, 2018</b>	<b>January 31, 2018</b>
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Deposits	\$ 110,929	\$ 12,325
Total current assets	110,929	12,325
<b>TOTAL ASSETS</b>	<b>\$ 110,929</b>	<b>\$ 12,325</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued expenses	\$ 458,480	\$ 458,480
Accounts payable to related party	83,692	83,692
Advances payable	3,450	3,450
Current portion of convertible notes payable, in default	230,833	—
Current portion of convertible notes payable, net of discount of \$333,832 and \$224,861, respectively	102,889	146,708
Current portion of accrued interest payable	103,406	55,343
Total current liabilities	982,750	747,673
Convertible notes payable, net of discount of \$0 and \$50,800, respectively	—	17,185
Accrued interest payable	—	11,939
<b>TOTAL LIABILITIES</b>	<b>982,750</b>	<b>776,797</b>
<b>COMMITMENTS AND CONTINGENCIES</b>	<b>—</b>	<b>—</b>
<b>STOCKHOLDERS' DEFICIT</b>		
Common stock, \$0.001 par value; 480,000,000 shares authorized; 28,791,079 and 6,839,274 shares issued and outstanding at October 31, 2018 and January 31, 2018, respectively	28,791	6,839
	1,000	1,000

Edgar Filing: NEUTRA CORP. - Form 10-Q

Series E preferred stock, \$0.001 par value; 20,000,000 shares authorized; 1,000,000 shares issued or outstanding at October 31, 2018 and January 31, 2018, respectively

Additional paid-in capital	7,516,358	5,661,911
Accumulated deficit	(8,417,970)	(6,434,222)
Total stockholders' deficit	(871,821)	(764,472)
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>	<b>\$ 110,929</b>	<b>\$ 12,325</b>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**NEUTRA CORP.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(UNAUDITED)**

	Nine months ended		Three months ended	
	October 31,		October 31,	
	2018	2017	2018	2017
REVENUE	\$ 2,006	\$ —	\$ —	\$ —
OPERATING EXPENSES				
General and administrative	1,633,387	116,285	1,507,186	25,842
LOSS FROM OPERATIONS	(1,631,381)	(116,285)	(1,507,186)	(25,842)
OTHER INCOME (EXPENSE)				
Interest expense	(352,367)	(302,288)	(206,251)	(28,590)
Total other income (expense)	(352,367)	(302,288)	(206,251)	(28,590)
NET LOSS	\$ (1,983,748)	\$ (418,573)	\$ (1,713,437)	\$ (54,432)
NET LOSS PER COMMON SHARE –				
Basic and fully diluted	\$ (0.21)	\$ (0.09)	\$ (0.12)	\$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and fully diluted	9,303,902	4,887,756	13,794,138	6,196,810

The accompanying notes are an integral part of these unaudited consolidated financial statements.



## NEUTRA CORP.

## CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(UNAUDITED)

	Common Stock		Series E Preferred Stock		Additional Paid-In Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount			
<b>BALANCE, January 31, 2017</b>	2,981,660	\$ 2,982	1,000,000	\$ 1,000	\$ 5,235,652	\$ (5,915,190)	(675,556)
Common stock issued for debt conversion	3,857,614	3,857	—	—	241,333	—	245,190
Beneficial conversion discount on issuance of convertible note payable	—	—	—	—	184,926	—	184,926
Net loss	—	—	—	—	—	(519,032)	(519,032)
<b>BALANCE, January 31, 2018</b>	6,839,274	\$ 6,839	1,000,000	\$ 1,000	\$ 5,661,911	\$ (6,434,222)	(764,472)
Common stock issued for debt conversion	1,951,805	1,952	—	—	73,447	—	75,399
Beneficial conversion discount on issuance of convertible note payable	—	—	—	—	337,000	—	337,000
Common stock issued to CEO for services	20,000,000	20,000	—	—	1,444,000	—	1,464,000
Net loss	—	—	—	—	—	(1,983,748)	(1,983,748)
<b>BALANCE, October 31, 2018</b>	28,791,079	\$ 28,791	1,000,000	\$ 1,000	\$ 7,516,358	\$ (8,417,970)	(871,821)

The accompanying notes are an integral part of these unaudited consolidated financial statements.



**NEUTRA CORP.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**

	<b>Nine months ended October 31,</b>	
	<b>2018</b>	<b>2017</b>
<b>CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Loss	\$ (1,983,748)	\$ (418,573)
Adjustments to reconcile net loss to net cash used in operating activities:		
Amortization of discount on convertible note payable	298,567	269,595
Issuance of common stock to CEO for services	1,464,000	—
Changes in operating assets and liabilities:		
Deposits	(98,604)	15,550
Accounts payable and accrued liabilities	—	(52,604)
Accounts payable to related party	—	38,892
Accrued interest payable	37,785	38,215
<b>NET CASH USED IN OPERATING ACTIVITIES</b>	<b>(282,000)</b>	<b>(108,925)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from convertible notes payable	337,000	108,925
Repayments of convertible notes payable	(55,000)	—
<b>NET CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>282,000</b>	<b>108,925</b>
<b>NET INCREASE (DECREASE) IN CASH</b>	<b>—</b>	<b>—</b>
<b>CASH, at the beginning of the period</b>	<b>—</b>	<b>—</b>
<b>CASH, at the end of the period</b>	<b>\$ —</b>	<b>\$ —</b>
<b>Supplemental Disclosures of Cash Flow Information:</b>		
Cash paid during the period for:		
Interest	\$ —	\$ —
Taxes	\$ —	\$ —
Noncash investing and financing transaction:		
Beneficial conversion discount on convertible note payable	\$ 337,000	\$ 146,926
Conversion of convertible notes payable.	\$ 75,399	\$ 222,615
Deposit received for convertible note payable	\$ —	\$ 38,000

The accompanying notes are an integral part of these unaudited consolidated financial statements.



**NEUTRA CORP.**

**NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

**OCTOBER 31, 2018**

**Note 1. General Organization and Business**

Neutra Corp. was incorporated in Nevada on January 11, 2011 to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how it grows, what it grows and how it consumes cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, Neutra Corp. is constantly combing the industry for the latest and greatest to test, prove and bring to market.

We have not generated any revenues to date and our activities have been limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

**Note 2. Going Concern**

The accompanying financial statements have been prepared assuming that we will continue as a going concern. For the nine months ended October 31, 2018, we had a net loss of \$1,983,748 and negative cash flow from operating activities of \$282,000. As of October 31, 2018, we had negative working capital of \$871,821. Management does not anticipate having positive cash flow from operations in the near future.

These factors raise a substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

We do not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the we will not be able to remain in business.

Management has plans to address the Company's financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement our business plan. Management will continue to seek out debt financing to obtain the capital required to meet our financial obligations. There is no assurance, however, that lenders will continue to advance capital to us or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about our ability to continue as a going concern.

In the long term, management believes that our projects and initiatives will be successful and will provide cash flow, which will be used to finance our future growth. However, there can be no assurances that our planned activities will be successful, or that we will ultimately attain profitability. Our long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and our ability to achieve adequate profitability and cash flows from operations to sustain its operations.

### **Note 3. Summary of Significant Accounting Policies**

#### **Interim Financial Statements**

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended January 31, 2018 and notes thereto and other pertinent information contained in our Form 10-K that we filed with the Securities and Exchange Commission (the “SEC”).

The results of operations for the nine-month period ended October 31, 2018 are not necessarily indicative of the results to be expected for the full fiscal year ending January 31, 2019.

#### **Consolidated Financial Statements**

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries from the date of their formations. Significant intercompany transactions have been eliminated in consolidation.

#### **Use of Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

#### **Earnings (Loss) per Common Share**

We compute basic and diluted earnings per common share amounts in accordance with ASC Topic 260, *Earnings per Share*. The basic earnings (loss) per common share are calculated by dividing our net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing our net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.

### **Recently Issued Accounting Pronouncements**

We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

### **Note 4. Related Party Transactions**

During the nine months ended October 31, 2018, we incurred salary expense of \$61,000 related to services provided by our former CEO Christopher Brown. We paid Mr. Brown \$61,000 in salary during the nine months ended October 31, 2018. As of October 31, 2018, we owe Mr. Brown \$89,200, which is recorded on the balance sheet in “Accounts Payable - Related Party.”

During the nine months ended October 31, 2018, we incurred and paid salary expense of \$7,500 related to services provided by our current CEO Sydney Jim. Additionally, on October 2, 2018, we issued 20,000,000 shares of common stock to Mr. Jim for services. The shares were valued at \$1,464,000 based on the fair market value of the stock on the date of issuance.

### **Note 5. Advances**

As of October 31, 2018 and January 31, 2018, we had amounts due under advances of \$3,450 at each period. These advances are not collateralized, non-interest bearing and are due on demand.





**Note 6. Convertible Notes Payable**

Convertible notes payable consists of the following as of October 31, 2018 and January 31, 2018:

	<b>October 31, 2018</b>	<b>January 31, 2018</b>
Convertible note, dated October 31, 2015, bearing interest at 10% per annum, maturing on October 31, 2017 and convertible into shares of common stock at \$0.01 per share, in default	72,640	72,640
Convertible note, dated October 31, 2015, bearing interest at 10% per annum, maturing on October 31, 2018 and convertible into shares of common stock at \$0.50 per share	156,976	156,976
Convertible note, dated January 31, 2016, bearing interest at 10% per annum, maturing on January 31, 2019 and convertible into shares of common stock at a 60% discount to the market price	82,735	82,735
Convertible note, dated March 14, 2016, bearing interest at 8% per annum, maturing on March 14, 2017, and convertible into shares of common stock at a 5% discount to the market price, in default	1,217	1,217
Convertible note, dated May 26, 2016, bearing interest at 8% per annum, maturing on May 26, 2017, and convertible into shares of common stock at a 45% discount to the market price, in default	67,986	67,986
Convertible note, dated September 6, 2016, bearing interest at 8% per annum, maturing September 6, 2017, and convertible into shares of common stock at a 45% discount to the lowest trading price in the 20 days prior to conversion with a floor on the conversion price of \$0.00005	—	18,000
Convertible note, dated September 6, 2016, bearing interest at 8% per annum, maturing September 6, 2017, and convertible into shares of common stock at a 45% discount to the lowest trading price in the 20 days prior to conversion with a floor on the conversion price of \$0.00005, in default	—	40,000
Convertible note, dated February 6, 2018, bearing interest at 8% per annum, maturing November 6, 2018, and convertible into shares of common stock at a 45% discount to the lowest trading price in the 20 days prior to conversion with a floor on the conversion price of \$0.00005	150,000	—
Convertible note, dated February 6, 2018, bearing interest at 8% per annum, maturing November 6, 2018, and convertible into shares of common stock at a 45% discount to the lowest trading price in the 20 days prior to conversion with a floor on the conversion price of \$0.00005	136,000	—
Convertible note, dated October 10, 2018, bearing interest at 8% per annum, maturing July 17, 2019, and convertible into shares of common stock at a 39% discount to the lowest trading price in the 15 days prior to conversion	—	—

Edgar Filing: NEUTRA CORP. - Form 10-Q

Total convertible notes payable	\$	517,554	\$	439,554
Less: current portion of convertible notes payable		(517,554)		(371,569)
Less: discount on noncurrent convertible notes payable		—		(50,800)
Convertible notes payable - non-current, net of discount	\$	—	\$	17,185
Current portion of convertible notes payable	\$	517,554	\$	371,569
Less: discount on current convertible notes payable		(333,832)		(224,861)
Convertible notes payable, net of discount	\$	333,722	\$	146,708

**Issuance of Convertible Promissory Notes**

During the nine months ended October 31, 2018 and 2017, we issued Convertible Promissory Notes. The Convertible Promissory Notes bear interest and are payable at maturity along with accrued interest. The Convertible Promissory Notes and unpaid accrued interest are convertible into common stock at the option of the holder.

<b>Date Issued</b>	<b>Maturity Date</b>	<b>Interest Rate</b>	<b>Conversion Rate</b>	<b>Amount of Note</b>
February 6, 2018	November 6, 2018	8%	45% discount	\$ 150,000
October 10, 2018	July 17, 2019	8%	39% discount	\$ 55,000
October 23, 2018	October 23, 2019	8%	45% discount	\$ 150,000

<b>Date Issued/Funded</b>	<b>Maturity Date</b>	<b>Interest Rate</b>	<b>Conversion Rate</b>	<b>Amount of Note</b>	
February 9, 2017	March 14, 2017	8%	45% discount	\$	48,449
April 27, 2017	May 27, 2017	8%	45% discount	\$	75,000
September 9, 2017	September 9, 2018	8%	45% discount	\$	40,000

We evaluated the terms of the new notes in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity's Own Stock* and determined that the underlying common stock is indexed to the Company's common stock. We determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, each of the above notes was fully discounted with a beneficial conversion discount on the date of issuance. We recorded the beneficial conversion discounts as an increase in additional paid-in capital and a discount to the Convertible Notes Payable. Discounts to the Convertible Notes Payable are amortized to interest expense over the life of the respective notes using the effective interest method. During the nine months ended October 31, 2018 and 2017, we recorded amortization of discounts on convertible notes payable and recognized interest expense of \$298,567 and \$269,595, respectively.

#### **Convertible Promissory Notes Issued for Cash**

On February 6, 2018, we issued a convertible promissory note to a third party for cash. The note (the "front-end note") was in the amount of \$150,000, and it matures on November 6, 2018. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005.

We evaluated the terms of the note in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity's Own Stock* and determined that the underlying common stock is indexed to the Company's common stock. We determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, we recognized beneficial conversion discount of \$142,500 on February 6, 2018. We recorded the beneficial conversion discount as an increase in additional paid-in capital and a discount to the Convertible Notes Payable. Discounts to the Convertible Notes Payable are amortized to interest expense using the effective interest method over the life of the respective notes.

On October 10, 2018, we issued a convertible promissory note to a third party for cash received of \$52,000. The note was in the amount of \$55,000, and it matures on July 17, 2019. The note bears interest at 8% per year and is convertible into shares of our common stock at a 39% discount to our lowest trading price over the preceding 15 days.

On October 23, 2018, we issued a convertible promissory note to the same third party for cash. The note (the “back-end note”) was in the amount of \$150,000, and it matures on October 23, 2019. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005.

We evaluated the terms of the note in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity’s Own Stock* and determined that the underlying common stock is indexed to the Company’s common stock. We determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, we recognized beneficial conversion discount of \$142,500 on October 23, 2018. We recorded the beneficial conversion discount as an increase in additional paid-in capital and a discount to the Convertible Notes Payable. Discounts to the Convertible Notes Payable are amortized to interest expense using the effective interest method over the life of the respective notes.

#### **Repayment of Convertible Promissory Note Issued for Cash**

On October 10, 2018, we issued a convertible promissory note to a third party for cash received of \$52,000. The note was in the amount of \$55,000, and it matures on July 17, 2019. The note bears interest at 8% per year and is convertible into shares of our common stock at a 39% discount to our lowest trading price over the preceding 15 days.

This note was paid in full on October 31, 2018 with a payment of \$63,514 including principal, accrued interest and prepayment penalties.

**Conversions to Common Stock**

During nine months ended October 31, 2017, the holders of our convertible promissory notes converted \$222,615 of principal and accrued interest into 3,244,944 shares of our common stock. See Note 7. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion.

During nine months ended October 31, 2018, the holders of our convertible promissory notes converted \$75,399 of principal and accrued interest into 1,951,805 shares of our common stock. See Note 7. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion.

**Note 7. Stockholders' Equity**

On October 2, 2018, we issued 20,000,000 shares of common stock to Mr. Jim for services. The shares were valued at \$1,464,000 based on the fair market value of the stock on the date of the employment agreement.

**Conversions to common stock**

During nine months ended October 31, 2018, the holders of our convertible notes elected to convert principal and interest into shares of common stock as detailed below:

<b>Date</b>	<b>Amount Converted</b>	<b>Number of Shares Issued</b>
April 26, 2018	\$ 18,904	343,709
September 12, 2018	21,209	550,094
September 28, 2018	21,280	552,727
October 25, 2018	14,006	505,275
<b>Total</b>	<b>\$ 75,399</b>	<b>1,951,805</b>

During nine months ended October 31, 2017, the holders of our convertible notes elected to convert principal and interest into shares of common stock as detailed below:

**Date**

	<b>Amount Converted</b>	<b>Number of Shares Issued</b>
February 13, 2017	\$ 16,619	151,085
February 22, 2017	25,066	227,870
March 6, 2017	23,629	214,807
March 21, 2017	12,784	102,168
March 30, 2017	21,346	170,595
April 7, 2017	10,690	92,558
April 20, 2017	35,372	321,567
May 22, 2017	10,055	130,582
May 30, 2017	650	65,000
June 2, 2017	10,079	160,748
June 2, 2017	650	65,000
June 13, 2017	11,113	202,060
June 30, 2017	10,140	290,344
July 12, 2017	10,167	308,078
July 25, 2017	13,255	401,624
August 8, 2017	11,000	340,858
<b>Total</b>	<b>\$ 222,615</b>	<b>3,244,944</b>

**Note 8. Subsequent Events**

On November 5, 2018, the Company issued 965,252 shares of common stock upon conversion of our convertible note payable in the principal and interest amount of \$11,000.

On November 29, 2018, the Company issued 2,425,253 shares of common stock upon conversion of our convertible note payable in the principal and interest amount of \$26,678.

## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

### **Overview**

Neutra Corp. was incorporated in Nevada on January 11, 2011 to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how it grows, what it grows and how it consumes cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, Neutra Corp. is constantly combing the industry for the latest and greatest to test, prove and bring to market.

We have generated limited revenues to date and our activities have been primarily limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

### **Critical Accounting Policies**

We prepare our Consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the condensed Consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.



While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report for the year ended January 31, 2018 on Form 10-K.

## **Results of Operations**

### **Nine months ended October 31, 2018 compared to the nine months ended October 31, 2017.**

#### Revenue

We recognized revenue of \$2,006 for the nine months ended October 31, 2018 related to our agreement with Artillery.

#### General and Administrative Expenses

We recognized general and administrative expenses of \$1,633,387 and \$116,285 for the nine months ended October 31, 2018 and 2017, respectively. The increase is primarily due to increased stock compensation expense related to our issuance of 20,000,000 shares to our CEO valued at \$1,464,000 and professional fees related to the preparation and filing of the Form S-1.

#### Interest Expense

Interest expense increased from \$302,288 for the nine months ended October 31, 2017 to \$352,367 for the nine months ended October 31, 2018. During the nine months ended October 31, 2018, we amortized \$298,567 of the discount on our convertible notes, compared to \$269,595 for the comparable period of 2017. This was driven by fewer conversions of our convertible notes payable into common stock. The remaining interest expense of \$53,800 and \$32,693 for the nine months ended October 31, 2018 and 2017, respectively, is related to the stated interest on our convertible promissory notes and prepayment penalties on the repayment of our convertible note payable in the amount of \$55,000.



Net Loss

We incurred a net loss of \$1,983,748 for nine months ended October 31, 2018 as compared to \$418,573 for the comparable period of 2017. The increased net loss is due to the increase in general and administrative expenses and interest expense

**Three months ended October 31, 2018 compared to the three months ended October 31, 2017.**

General and Administrative Expenses

We recognized general and administrative expenses of \$1,507,186 and \$25,842 for the three months ended October 31, 2018 and 2017, respectively. The increase is primarily due to stock compensation expense related to our issuance of 20,000,000 shares to our CEO valued at \$1,464,000 and increased professional fees related to the preparation and filing of the Form S-1.

Interest Expense

Interest expense increased from \$28,590 for the three months ended October 31, 2017 to \$206,251 for the three months ended October 31, 2018. During the three months ended October 31, 2018, we amortized \$62,701 of the discount on our convertible notes, compared to \$109,772 for the comparable period of 2017. This was driven by fewer conversions of our convertible notes payable into common stock. The remaining interest expense of \$13,417 and \$9,818 for the three months ended October 31, 2018 and 2017, respectively, is related to the stated interest on our convertible promissory notes.

Net Loss

We incurred a net loss of \$1,713,437 for three months ended October 31, 2018 as compared to \$54,432 for the comparable period of 2017. The increased net loss is due to the increase in general and administrative expense and interest expense.

At October 31, 2018, we had cash on hand of \$0. We have negative working capital of \$871,821. Net cash used in operating activities for the nine months ended October 31, 2018 was \$282,000. Cash on hand is adequate to fund our operations for less than one month. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to us. We have no material commitments for capital expenditures as of October 31, 2018.

### **Additional Financing**

Additional financing is required to continue operations. Although actively searching for available capital, we do not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

### **Off Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

## **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

This item is not applicable to smaller reporting companies.

## **ITEM 4. CONTROLS AND PROCEDURES**

### **Management's Report on Internal Control over Financial Reporting**

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of October 31, 2018. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of October 31, 2018, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the

required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

1. As of October 31, 2018, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees our accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.
2. As of October 31, 2018, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.
3. As of October 31, 2018, we did not establish a formal written policy for the approval, identification and authorization of related party transactions.

Our management, including our principal executive officer and principal financial officer, who is the same person, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

### **Change in Internal Controls Over Financial Reporting**

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

## **PART II — OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

**ITEM 1A. RISK FACTORS**

This item is not applicable to smaller reporting companies.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

During three months ended October 31, 2018, the holders of our convertible notes elected to convert principal and interest into shares of common stock as detailed below:

<b>Date</b>		<b>Amount Converted</b>	<b>Number of Shares Issued</b>
September 12, 2018	\$	21,209	550,094
September 28, 2018		21,280	552,727
October 25, 2018		14,006	505,275
<b>Total</b>	<b>\$</b>	<b>56,495</b>	<b>1,608,096</b>

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

We have not defaulted upon senior securities.

**ITEM 4. MINE SAFETY DISCLOSURES**

This item is not applicable to the Company.

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

3.1 Articles of Incorporation (1)

3.2 Bylaws (1)

14.1 Code of Ethics (1)

31.1 Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial and accounting officer. (2)

32.1 Section 1350 Certification of principal executive officer and principal financial accounting officer. (2)

101 XBRL data files of Financial Statement and Notes contained in this Quarterly Report on Form 10-Q. (2)(3)

(1) Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on February 24, 2011.

(2) Filed or furnished herewith.

(3) To be submitted by amendment.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Neutra Corp.

Date: December 17, 2018

BY: /s/ Sydney Jim  
Sydney Jim



President, Secretary, Treasurer, Principal Executive  
Officer,

Principal Financial and Accounting Officer, and Sole  
Director

- 16 -

---